Patents by Inventor Michael Lowinger

Michael Lowinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONIST
    Publication number: 20240261299
    Abstract: The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.
    Type: Application
    Filed: April 9, 2024
    Publication date: August 8, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Paul A. Harmon, Narayan Variankaval, Michael Lowinger, Chad David Brown, Francis Flanagan
  • Solid dosage formulations of an orexin receptor antagonist
    Patent number: 11980623
    Abstract: The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: May 14, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Paul A. Harmon, Narayan Variankaval, Michael Lowinger, Chad David Brown, Francis Flanagan
  • COMPOSITION OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR
    Publication number: 20160287568
    Abstract: The invention encompasses a composition comprising the reverse transcriptase (“RT”) inhibitor 3-chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile sufficiently mixed in a concentration enhancing polymer, and processes for making the same. The composition and processes of the present invention significantly improve the bioavailability of the aforementioned RT inhibitor, while maintaining physical stability.
    Type: Application
    Filed: November 19, 2014
    Publication date: October 6, 2016
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Michael Lowinger, Aditya S. Tatavarti, Patrick Jules Marsac, Kristin J.M. Ploeger, John M. Baumann, Corey J. Bloom, Katherine Anne Brookhart
  • Polymer formulations of CETP inhibitors
    Patent number: 8030359
    Abstract: A pharmaceutical composition comprises (a) a CETP inhibiting compound, or a pharmaceutically acceptable salt thereof; (b) a concentration-enhancing polymer, and (c) optionally one or more surfactants; wherein the compound has the structure shown as Formula I below. The composition raises HDL-cholesterol and lowers LDL-cholesterol.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: October 4, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Sarah Geers, Michael Lowinger, Craig A. McKelvey, Robert F. Meyer, Dina Zhang
  • Polymer Formulations of CETP Inhibitors
    Publication number: 20100227903
    Abstract: A pharmaceutical composition comprises (a) a CETP inhibiting compound, or a pharmaceutically acceptable salt thereof; (b) a concentration-enhancing polymer, and (c) optionally one or more surfactants; wherein the compound has the structure shown as Formula I below. The composition raises HDL-cholesterol and lowers LDL-cholesterol.
    Type: Application
    Filed: February 9, 2007
    Publication date: September 9, 2010
    Applicant: MERCK & CO., INC.
    Inventors: Sarah Geers, Michael Lowinger, Craig A. McKelvey, Robert F. Meyer, Dina Zhang